FLT3 and acute myeloid leukemia: In association with definitive chemotherapy, sorafenib lengthens the survival of a patient with increased toxicity under 60 years of age.74, 81In phase 2 clinical trial, sorafenib and omacetaxine mepesuccinate proved as a successful therapy for AML patients with a mutation in FLT3-ITD.